Back to Search Start Over

Prognostic Value ofEGFRExon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

Authors :
Marketa Cernovska
Leona Koubková
Kristina Sandstrom
Jana Krejčí
Martin Svaton
Monika Bratová
Jiri Blazek
Jana Skrickova
P. Opálka
Helena Čoupková
Michal Hrnčiarik
Ondrej Fischer
Karolina Hurdalkova
Daniel Dolezal
Tana Tuzova
Magda Barinova
Milada Zemanova
Péter Kunovszki
Lubos Holubec
Miloš Pešek
P. Mahadevia
Source :
Anticancer Research. 41:5625-5634
Publication Year :
2021
Publisher :
Anticancer Research USA Inc., 2021.

Abstract

Background/aim Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. Patients and methods We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. Results We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. Conclusion Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.

Details

ISSN :
17917530 and 02507005
Volume :
41
Database :
OpenAIRE
Journal :
Anticancer Research
Accession number :
edsair.doi...........aba859470439e22e1b459a0e725153a0
Full Text :
https://doi.org/10.21873/anticanres.15378